Skip to main content

Advertisement

Table 2 Correlation of genetic alteration according to the various criteria

From: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer

Characteristics Amplification GCN gain ASCO/CAP criteria
Negative Positive P CN <4 4≤ CN P Negative Equivocal Positive P
EGFR
 Location    1.000    0.803     0.419
  Right colon 91 (97.8%) 2 (2.2%)   89 (95.7%) 4 (4.3%)   89 (95.7%) 2 (2.2%) 2 (2.2%)  
  Left colon 124 (97.6%) 3 (2.4%)   123 (96.9%) 4 (3.1%)   123 (96.9%) 0 (0%) 4 (3.1%)  
  Rectum 111 (97.4%) 3 (2.6%)   111 (97.4%) 3 (2.6%)   111 (97.4%) 0 (0%) 3 (2.6%)  
 pTNM stage    1.000    0.429     0.045
  I–III 266 (97.4%) 7 (2.6%)   265 (97.1%) 8 (2.9%)   265 (97.1%) 0 (0%) 8 (2.9%)  
  IV 60 (98.4%) 1 (1.6%)   58 (95.1%) 3 (4.9%)   58 (95.1%) 2 (3.3%) 1 (1.6%)  
 MSI status (n = 323)    1.000    0.609     1.000
  MSS/MSI-L 288 (97.3%) 8 (2.7%)   285 (96.3%) 11 (3.7%)   285 (96.3%) 2 (0.7%) 9 (3.0%)  
  MSI-H 27 (100%) 0 (0%)   27 (100%) 0 (0%)   27 (100%) 0 (0%) 0 (0%)  
HER2
 Location    0.011    0.073     0.015
  Right colon 90 (96.8%) 3 (3.2%)   89 (95.7%) 4 (4.3%)   89 (95.7%) 1 (1.1%) 3 (3.2%)  
  Left colon 123 (96.9%) 4 (3.1%)   117 (92.1%) 10 (7.9%)   116 (91.3%) 7 (5.5%) 4 (3.1%)  
  Rectum 101 (88.6%) 13 (11.4%)   99 (86.8%) 15 (13.2%)   99 (86.8%) 2 (1.8%) 13 (11.4%)  
 pTNM stage    1.000    0.248     0.422
  I–III 256 (93.8%) 17 (6.2%)   247 (90.5%) 26 (9.5%)   246 (90.1%) 10 (3.7%) 17 (6.2%)  
  IV 58 (95.1%) 3 (4.9%)   58 (95.1%) 3 (4.9%)   58 (95.1%) 0 (0%) 3 (4.9%)  
MSI status (n = 323)    1.000    0.491     1.000
 MSS/MSI-L 278 (93.9%) 18 (6.1%)   269 (90.9%) 27 (9.1%)   268 (90.5%) 10 (3.4%) 18 (6.1%)  
  MSI-H 26 (96.3%) 1 (3.7%)   26 (96.3%) 1 (3.7%)   26 (96.3%) 0 (0%) 1 (3.7%)  
c-MYC
 Location    0.056    0.042     0.083
  Right colon 88 (94.6%) 5 (5.4%)   82 (88.2%) 11 (11.8%)   82 (88.2%) 6 (6.5%) 5 (5.4%)  
  Left colon 110 (86.6%) 17 (13.4%)   96 (75.6%) 31 (24.4%)   96 (75.6%) 13 (10.2%) 18 (14.2%)  
  Rectum 107 (93.9%) 7 (6.1%)   96 (84.2%) 18 (15.8%)   96 (84.2%) 11 (9.6%) 7 (6.1%)  
 pTNM stage    0.723    0.136     0.199
  I–III 250 (91.6%) 23 (8.4%)   228 (83.5%) 45 (16.5%)   228 (83.5%) 21 (7.7%) 24 (8.8%)  
  IV 55 (90.2%) 6 (9.8%)   46 (75.4%) 15 (24.6%)   46 (75.4%) 9 (14.8%) 6 (9.8%)  
 MSI status (n = 323)    0.491    0.061     0.155
  MSS/MSI-L 269 (90.9%) 27 (9.1%)   240 (81.1%) 56 (18.9%)   240 (81.1%) 28 (9.5%) 28 (9.5%)  
  MSI-H 26 (96.3%) 1 (3.7%)   26 (96.3%) 1 (3.7%)   26 (96.3%) 0 (0%) 1 (3.7%)  
MET
 Location    0.427    0.602     0.536
  Right colon 87 (93.5%) 6 (6.5%)   77 (82.8%) 16 (17.2%)   75 (80.6%) 10 (10.8%) 8 (8.6%)  
  Left colon 122 (96.1%) 5 (3.9%)   109 (85.8%) 18 (14.2%)   106 (83.5%) 15 (11.8%) 6 (4.7%)  
  Rectum 111 (97.4%) 3 (2.6%)   100 (87.7% 14 (12.3%)   99 (86.8%) 11 (9.6%) 4 (3.5%)  
 pTNM stage    1.000    0.003     0.020
  I–III 261 (95.6%) 12 (4.4%)   241 (88.3%) 32 (11.7%)   235 (86.1%) 23 (8.4%) 15 (5.5%)  
  IV 59 (96.7%) 2 (3.3%)   45 (73.8%) 16 (26.2%)   45 (73.8%) 13 (21.3%) 3 (4.9%)  
 MSI status (n = 323)    0.609    0.147     0.298
  MSS/MSI-L 284 (95.9%) 12 (4.1%)   252 (85.1%) 44 (14.9%)   247 (83.4%) 33 (11.1%) 16 (5.4%)  
  MSI-H 27 (100%) 0 (0%)   26 (96.3%) 1 (3.7%)   26 (96.3%) 1 (3.7%) 0 (0%)  
  1. MSI microsatellite instability, MSS microsatellite instability stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, GCN gene copy number, CN copy number, ASCO/CAP American Society of Clinical Oncology/College of American Pathologists